Adalimumab-adbm and CYLTEZO® (adalimumab-adbm) injection

See why Adalimumab-adbm could give you the control you want

Adalimumab-adbm and CYLTEZO® are the exact same medicine

Adalimumab-adbm is:

The FDA first approved CYLTEZO as an interchangeable biosimilar (50 mg/mL) to Humira on October 15, 2021. CYLTEZO (100 mg/mL) was approved as an interchangeable biosimilar to Humira on May 20, 2025. For more information on interchangeability for CYLTEZO, refer to the FDA’s resource on biosimilars and interchangeability, the Purple Book: https://purplebooksearch.fda.gov/.

Adalimumab-adbm is a citrate-free, injectable prescription medicine called a tumor necrosis factor (TNF) blocker that is used for the following conditions:

Click here for full indications for Adalimumab-adbm and CYLTEZO.

Adalimumab-adbm side effects are similar to Humira

The most common side effects of Adalimumab-adbm included injection site reaction (redness, rash, swelling, itching, or bruising), upper respiratory infections (including sinus infections), and headaches.

These are not all the possible side effects with Adalimumab-adbm. Tell your doctor if you have any side effect that bothers you or that does not go away. Tell your doctor if you think you have an infection or have symptoms of an infection, such as fever, sweats, or chills; muscle aches; cough; shortness of breath; blood in phlegm; warm, red or painful skin or sores on your body; diarrhea or stomach pain; burning when you urinate or urinate more often than normal; feel very tired; and/or weight loss. Adalimumab-adbm can make you more likely to get infections or make any infection that you may have worse.

Click here to read Important Safety Information.

Frequently asked questions

About Adalimumab-adbm and CYLTEZO

What is Adalimumab-adbm or CYLTEZO?

Adalimumab-adbm, a biosimilar to Humira, may treat or reduce the signs and symptoms of certain autoimmune conditions. See Important Safety Information about Adalimumab-adbm.

Is Adalimumab-adbm the same as Humira®?

Adalimumab-adbm is an interchangeable* biosimilar to Humira. Adalimumab-adbm and CYLTEZO are the exact same medicine. Both Adalimumab-adbm and Humira are adalimumab products, and Adalimumab-adbm has been tested to make sure it is as effective and safe as Humira.

* The FDA first approved CYLTEZO as an interchangeable biosimilar (50 mg/mL) to Humira on October 15, 2021. CYLTEZO (100 mg/mL) was approved as an interchangeable biosimilar to Humira on May 20, 2025. For more information on interchangeability for CYLTEZO, refer to the FDA’s resource on biosimilars and interchangeability, the Purple Book: https://purplebooksearch.fda.gov/.

What are biologics, biosimilars, and interchangeable biosimilars?

Biologics are a type of medication made with a living source, such as a microorganism, plant cell, or animal cell.

A biosimilar, such as Adalimumab-adbm, is a type of biologic created based off a reference product. In this case, Humira is the reference product. A biosimilar is highly similar to and has no difference in safety and effectiveness from the existing FDA-approved reference product.

An interchangeable biosimilar generally requires an additional study, such as a switch study, before being approved by the FDA. The study must show that patients experienced no difference in effectiveness or increase in safety risk when switching back and forth between the original biologic, or reference, product and biosimilar, compared with those who remained on the original biologic product.

My medication says Adalimumab-adbm, not CYLTEZO. Are they the same?

Yes, Adalimumab-adbm and CYLTEZO are the exact same medicine with the same effectiveness and safety.

Why did I receive Adalimumab-adbm and not CYLTEZO?

Adalimumab-adbm and CYLTEZO are the exact same medicine with the same effectiveness and safety. Whether you receive Adalimumab-adbm or CYLTEZO depends on which product is covered by your insurance plan. A specialty pharmacy may have worked with your healthcare provider and insurance company for you to receive Adalimumab-adbm.

Effectiveness, safety, and side effects

Is Adalimumab-adbm effective for my condition?

Yes. A range of clinical studies with adalimumab showed the medication to be effective and safe in the treatment of rheumatoid arthritis, plaque psoriasis, Crohn’s disease, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, hidradenitis suppurativa, juvenile idiopathic arthritis, and uveitis.

The FDA designated Adalimumab-adbm as an interchangeable* biosimilar to Humira. Adalimumab-adbm and CYLTEZO are the exact same medicine, and the FDA designated Adalimumab-adbm as an interchangeable* biosimilar to Humira. This designation was based on an additional study in which patients were switched back and forth from Humira to CYLTEZO, with no change in effectiveness or safety in any given patient. The FDA only gives the interchangeable designation based on additional information. This is generally from one or more studies that confirm the biosimilar's effectiveness and safety are the same as the original branded product in any given patient.

What is the most important information I should know about Adalimumab-adbm?

Adalimumab-adbm is a medicine that affects your immune system. It can lower the ability of your immune system to fight infections. Serious infections have happened in people taking adalimumab products. These serious infections include tuberculosis (TB) and infections caused by viruses, fungi, or bacteria that have spread throughout the body. Some people have died from these infections.

Your doctor should test you for TB before starting Adalimumab-adbm. Your doctor should check you closely for signs and symptoms of TB during treatment with Adalimumab-adbm.

You should not start taking Adalimumab-adbm if you have any kind of infection unless your doctor says it is okay.

Is Adalimumab-adbm safe for me to use?

The FDA approved Adalimumab-adbm as a biosimilar and additionally designated Adalimumab-adbm (the exact same medicine as CYLTEZO) as an interchangeable* biosimilar to Humira. This designation was based in part on data from an additional study, in which patients were switched back and forth from Humira to CYLTEZO, with no meaningful difference in effectiveness or safety compared with patients who remained on Humira.

What are the possible side effects of Adalimumab-adbm?

The most common side effects of Adalimumab-adbm include injection site reactions: redness, rash, swelling, itching, or bruising. These are not all the possible side effects with Adalimumab-adbm. Tell your doctor if you have any side effect that bothers you or that does not go away. Additional side effects include upper respiratory infections (including sinus infections), headaches, and rash.

Tell your doctor if you have any side effect that bothers you or that does not go away. Tell your doctor if you think you have an infection or have symptoms of an infection, such as fever, sweats, or chills; muscle aches; cough; shortness of breath; blood in phlegm; warm, red or painful skin or sores on your body; diarrhea or stomach pain; burning when you urinate or urinate more often than normal; feel very tired; and/or weight loss. Adalimumab-adbm can make you more likely to get infections or make any infection that you may have worse.

For full details, please see the Medication Guide.

What kinds of results can I expect to see if I use Adalimumab-adbm instead of Humira?

You can expect the same results that you experienced with Humira.

How long until I start seeing results with Adalimumab-adbm?

Your doctor can provide guidance on the efficacy of Adalimumab-adbm for your condition. If you have any questions regarding the use of Adalimum-abdm or if you experience any side effects, please contact your doctor right away. If you are starting treatment with adalimumab, please follow your doctor's prescription. You can refer to the full Prescribing Information for more information about Adalimumab-adbm. If you do not notice any improvement or experience worsening of symptoms after several weeks, consult with your doctor to determine if Adalimumab-adbm is the appropriate medication for you.

For patients switched from Humira to Adalimumab-adbm, you can expect the same clinical results as Humira immediately. Because you already had the required starting dose with Humira, you will start Adalimumab-adbm by continuing to take maintenance doses with Adalimumab-adbm.

What if Adalimumab-adbm does not work for me?

Although some patients may experience positive results, others may not. Therefore, it is essential that you discuss with your doctor the efficacy of Adalimumab-adbm for your condition. If you have questions regarding the use of Adalimumab-adbm, please don't hesitate to speak with your doctor.

Is it safe to take Adalimumab-adbm if I am taking other medications?

Before starting Adalimumab-adbm, you should tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Show your doctor and pharmacist a list of medicines you are currently taking when you are getting a new medicine.

Especially tell your doctor if you use ORENCIA® (abatacept), KINERET® (anakinra), REMICADE® (infliximab), ENBREL® (etanercept), CIMZIA® (certolizumab pegol), or SIMPONI® (golimumab), because you should not use Adalimumab-adbm while you are also using one of these medicines. Your doctor may not want to give you Adalimumab-adbm if you have received RITUXAN® (rituximab) recently, IMURAN® (azathioprine), or PURINETHOL® (6-mercaptopurine, 6-MP).

Am I allowed to take Adalimumab-adbm if I am pregnant, expect to become pregnant, or am breastfeeding?

Before starting Adalimumab-adbm, tell your doctor if you are pregnant, plan to become pregnant, are breastfeeding, or plan to breastfeed. In such cases, Adalimumab-adbm may not be right for you. You and your doctor should decide if you should take Adalimumab-adbm while you are pregnant or breastfeeding.

If you have a baby and you were using Adalimumab-adbm during your pregnancy, tell your pediatrician before your baby receives any vaccines.

Could I get COVID-19, influenza, or other vaccines when I am using Adalimumab-adbm?

Talk to your doctor about which vaccines are right for you. You may receive vaccines, except for live vaccines, while using Adalimumab-adbm. It is recommended that pediatric patients, if possible, be up to date with all immunizations that follow current immunization guidelines before starting Adalimumab-adbm. Please speak with your pediatrician.

Taking Adalimumab-adbm

How do I use Adalimumab-adbm?

Adalimumab-adbm is injected under the skin using either an Adalimumab-adbm pen or a prefilled syringe. Both were designed to be used at home so that you can inject on a set schedule, using the right dose prescribed by your doctor. Speak to your doctor before starting injections on your own to ensure that you have the proper injection training.

You can find information about how to inject CYLTEZO here.

What dosage of CYLTEZO or Adalimumab-adbm should I use?

The appropriate dosage of Adalimumab-adbm is prescribed by your doctor, based on your condition. Please follow the dosing instructions provided by your doctor.

What if I miss a dose?

Do not miss any doses of Adalimumab-adbm unless your doctor says it is okay. If you forget to take Adalimumab-adbm, inject a dose as soon as you remember. Then, take your next dose at your scheduled time. This will put you back on schedule. In case you are not sure when to inject Adalimumab-adbm, call your doctor or pharmacist.

If you take more Adalimumab-adbm than you were told to take, call your doctor.

How many doses of Adalimumab-adbm will my specialty pharmacy send me at one time, and how often will I get a supply of Adalimumab-adbm?

Your Adalimumab-adbm prescription and shipment frequency will be determined by your doctor and your insurance coverage.

Contact your specialty pharmacy with questions regarding refills.

What if my Adalimumab-adbm pen is unusable?

If one or more of your Adalimumab-adbm pens or prefilled syringes meets at least one of the following criteria, do not use it and contact the specialty pharmacy to request a replacement.

What if I have extra pens or prefilled syringes when my new doses arrive?

You may use the Adalimumab-adbm products you have as long as they have not expired. Check the date on the packaging. If the expiration date has passed, discard the entire Adalimumab-adbm pen or prefilled syringe in your sharps disposal container, and use an Adalimumab-adbm pen or prefilled syringe that has not yet expired.

Storing Adalimumab-adbm

How do I store Adalimumab-adbm?

Adalimumab-adbm must be refrigerated between 36° F and 46° F. Do not freeze Adalimumab-adbm. Do not use Adalimumab-adbm if frozen, even if it has been thawed. Do not store Adalimumab-adbm in extreme heat or cold. Adalimumab-adbm must be stored in its original carton until the time of injection to protect it from light.

How long can I store Adalimumab-adbm in the refrigerator?

If stored as directed, Adalimumab-adbm can be used up to the expiration date printed on the carton. Do not use Adalimum-abdm after its expiration date.

Once I’ve let Adalimumab-adbm warm up to room temperature, can I put it back in the refrigerator and use it at some other time?

No, you should not put Adalimumab-adbm back in the refrigerator after you have let it warm up to room temperature. However, Adalimumab-adbm may be stored at room temperature up to a maximum of 77° F for a period of up to 14 days, protected from light. If it is not used within that 14-day period, Adalimumab-adbm should be discarded.

Can I take Adalimumab-adbm with me when I travel?

Yes. When you are traveling, Adalimumab-adbm may be stored at room temperature up to a maximum of 77° F for a period of up to 14 days, protected from light. If it is not used within that 14-day period, Adalimumab-adbm should be discarded.

How do I safely dispose of Adalimumab-adbm pens and prefilled syringes?

Adalimumab-adbm pens and prefilled syringes must be disposed of immediately after use using a sharps disposal container. Sharps disposal containers should be kept safely beyond the reach of children.

Savings and support

Is there a Copay Program for Adalimumab-adbm?

The CareConnect4Me™ Adalimumab-adbm Copay Program is no longer accepting new enrollments as of May 1, 2026.

Patients who enrolled in the program prior to May 1, 2026 will continue to receive copay benefits through July 1, 2026. The final date to submit a claim for reimbursement is October 1, 2026. To submit a claim, please use this form.

If you have any questions, please call CARECONNECT4ME at 1-833-295-8396 Monday – Friday 8:00 AM to 8:00 PM ET.

Is Adalimumab-adbm covered by insurance?

Different insurance plans cover Adalimumab-adbm. You may have been prescribed Adalimumab-adbm because your insurance plan covers it.

How much does Adalimumab-adbm cost?

How much you pay for Adalimumab-adbm will depend on your insurance coverage.

Is Adalimumab-adbm cheaper than Humira?

The price of Adalimumab-adbm or Humira is based on an individual’s insurance plan.

Is Adalimumab-adbm covered by Medicare or Medicaid?

The Medicare Prescription Payment Plan (M3P) is a no-cost budgeting tool that helps you manage your medication costs with fixed monthly payments throughout the plan year. If you have a Medicare drug plan or Medicare Advantage plan that includes drug coverage, enrolling is simple and flexible, allowing you to opt in at any time each year. Visit third-party websites like the official government M3P website or Getmymeds.com for more information. Click below to enroll now.1

  1. We are sharing this information to help raise awareness about M3P for patients and their care partners. Boehringer Ingelheim is not affiliated with these third parties and does not sponsor or control the content on their websites. Inclusion of these links does not constitute an endorsement. GetMyMeds is not affiliated with the Centers for Medicare & Medicaid Services (the agency that administers Medicare) and it’s just one of several ways to enroll in M3P.

What if I need financial assistance?

You can explore the Foundation Dashboard Tool which is free to use and provides up-to-date information on independent third-party charitable organizations based on your particular disease indication. Each Foundation has its own eligibility criteria and list of information needed to process an application.

If you have any questions about eligibility, guidelines, or applications, you can contact the Foundation directly using the contact information provided on their website.

If you run into any issues with the dashboard, please call 1-866-488-7732, Monday-Friday, 9am-5pm ET, excluding holidays.